| Full text | |
| Author(s): |
Strauss, Bryan E.
[1]
;
Oliveira Silva, Gissele Rolemberg
[1]
;
Vieira, Igor de Luna
[1]
;
Dutra Cerqueira, Otto Luiz
[1]
;
Del Valle, Paulo Roberto
[1]
;
Vieira Medrano, Ruan Felipe
[1]
;
Mendonca, Samir Andrade
[1]
Total Authors: 7
|
| Affiliation: | [1] Univ Sao Paulo, Hosp Clin HCFMUSP, Ctr Invest Translac Oncol, Lab Vetores Virais, ICESP, Fac Med, Sao Paulo, SP - Brazil
Total Affiliations: 1
|
| Document type: | Review article |
| Source: | Clinics; v. 73, n. 1 2018. |
| Web of Science Citations: | 0 |
| Abstract | |
While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice) and the interferon-beta cDNA in our case, was shown to promote an antitumor immune response in mouse models of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy. The success of any translational research requires the cooperation of a multidisciplinary team of professionals involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo. (AU) | |
| FAPESP's process: | 12/05066-7 - Use of shRNA anti-hexon e anti-IVa2 during the production of adeno-associated virus as a strategy for eliminating helper adenovirus: Proof of principle |
| Grantee: | Marlous Vinícius Gomes Lana |
| Support Opportunities: | Scholarships in Brazil - Master |
| FAPESP's process: | 16/18197-3 - Investigation of the direct and paracrine angiogenic effects after gene transfer mediated by adenoviral vectors carrying the Interferon-beta in murine melanoma |
| Grantee: | Igor de Luna Vieira |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 13/09474-5 - Association of the immunotherapy mediated by p19Arf and Interferon-beta gene transfer with immunogenic cell death induced by the chemotherapic doxorubicin for the treatment of cancer |
| Grantee: | Ruan Felipe Vieira Medrano |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 13/25167-5 - P19Arf and interferon-beta gene transfer: delineating the importance of their combination in mouse models of cancer gene therapy |
| Grantee: | Bryan Eric Strauss |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 13/16074-3 - P53/ARF and interferon-beta pathways as targets for colorectal carcinoma gene therapy |
| Grantee: | Paulo Roberto Del Valle |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 15/26580-9 - Cancer gene therapy: strategic positioning for translational studies |
| Grantee: | Bryan Eric Strauss |
| Support Opportunities: | Research Projects - Thematic Grants |